China's medical products administrator included four BeiGene (HKG:6160, SHA:688235) drugs in the national medical insurance catalog, according to a Friday filing with the Shanghai Stock Exchange.
The products include Tislelizumab and Zebutinib for tumors, Baituowei for prostate and breast cancer, and Carfilzomib for myeloma, the filing said.
Shares rose 5% in Hong Kong and 3% in Shanghai during Friday's trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。